NASDAQ:LGND

Ligand Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy LGND

*Your capital is at risk

$287.54

-8.75 (-2.95%)

At Close: Jul 31, 2026

Ligand Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -50.46. In total, the insiders bought 208.31K and sold 44.51K LGND shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-50.46
● Buy	208.31K shares
● Sell	44.51K shares
48% Buy Activity Weak Positive Correlation
Sell Signal Medium Confidence Mar 04, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -50.46. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	600 Value: $136.5K
Apr 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	1 238 Value: $248.8K
Apr 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	700 Value: $141.3K
Apr 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	963 Value: $195.7K
Apr 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	337 Value: $68.9K
Apr 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	1 302 Value: $260.0K
Apr 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	460 Value: $91.5K
Apr 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	159 Value: $32.5K
Apr 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	43 Value: $9K
Apr 01, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Reardon Andrew Clo & Secretary	Officer	5 000 Value: $261.4K
Apr 01, 2026 Buy	Common Stock M-Exempt	Reardon Andrew Clo & Secretary	Officer	5 000 Value: $261.4K
Apr 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	79 Value: $16.0K
Apr 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	40 Value: $8K
Apr 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	146 Value: $29.2K
Mar 23, 2026 Sell	Common Stock S-Sale	Sabba Stephen L Director	Director	1 000 Value: $207.9K
Mar 11, 2026 Buy	Common Stock M-Exempt	Espinoza Octavio Chief Financial Officer	C-Suite Officer	2 405 Value: $222.8K
Mar 06, 2026 Buy	Common Stock M-Exempt	Lamattina John L Director	Director	2 161 Value: $246.7K
Mar 06, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Lamattina John L Director	Director	2 161 Value: $246.7K
Mar 06, 2026 Sell	Common Stock S-Sale	Lamattina John L Director	Director	2 161 Value: $433.8K
Mar 02, 2026 Buy	Employee Stock Option (right to buy) A-Award	Espinoza Octavio Chief Financial Officer	C-Suite Officer	23 527 Value: $4.77M
Mar 02, 2026 Buy	Common Stock A-Award	Davis Todd C Chief Executive Officer	CEO / President	10 495 Value: $2.13M
Mar 02, 2026 Buy	Employee Stock Option (right to buy) A-Award	Davis Todd C Chief Executive Officer	CEO / President	50 058 Value: $10.1M
Mar 02, 2026 Buy	Common Stock A-Award	Reardon Andrew Clo & Secretary	Officer	4 513 Value: $914.1K
Mar 02, 2026 Buy	Employee Stock Option (right to buy) A-Award	Reardon Andrew Clo & Secretary	Officer	21 525 Value: $4.36M
Mar 02, 2026 Buy	Common Stock A-Award	Espinoza Octavio Chief Financial Officer	C-Suite Officer	4 933 Value: $999.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LIGAND PHARMACEUTICALS INCORPORATED

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease ca...

Read Full Profile Here